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Sir,
We would like to give an update on a family with Lynch syndrome
(hereditary non-polyposis colorectal cancer, HNPCC) that we have
previously reported with germline truncating mutations in MSH2
(exon 8 deletion) and BRCA2 (542G4T) (Thiffault et al,2 0 0 4 ) .T h i s
was a 26-member kindred with five cases of colorectal cancer and five
cases of breast cancer, all but one of the cancers occurring below the
age of 45 years. We reported that one of the individuals who had been
diagnosed with rectal cancer (III.10 in original pedigree) also had a
keratoacanthoma. This type of skin lesion is seen in some families with
MSH2 or, less commonly, MLH1 mutations when it is termed Muir–
T o r r eS y n d r o m e( M T S )( P o n t ia n dP o n zd eL e o n ,2 0 0 5 ) .I m m u n o -
histochemistry (IHC) at the time showed normal MSH2 expression, so
we felt that this family did not belong to the MTS group. Subsequently,
the individual was diagnosed with two separate sebaceous carcinomas
on each arm. Immunohistochemistry analysis of these lesions shows
loss of MSH2 expression in both cases, one of which is shown in
Figure 1, confirming that this is in fact an MTS family.
This new development illustrates two points. Firstly the
Lynch syndrome and MTS phenotypes are pleiotropic and Lynch
syndrome can evolve into MTS in the same family. Lynch
syndrome is usually suspected when the Amsterdam Criteria are
fulfilled or the less-specific Bethesda guidelines are met. The
individual described here had an anal canal squamous carcinoma,
a cancer type not associated with Lynch syndrome, which was
microsatellite stable. His father, who was an obligate MSH2
mutation carrier, had a rectal cancer which is also unusual
(Hoogerbrugge et al, 2003), and an astrocytoma, raising the
possibility of overlap with another variant, Turcot syndrome.
Although Turcot syndrome was classically thought of as a
combination of brain tumours and polyposis and has been mainly
associated with mutations in the APC gene (Galiatsatos and
Foulkes, 2006), a minority are also due to mutation in the Lynch
syndrome genes, particularly biallelic PMS mutation carriers
(De Vos et al, 2006). Secondly, the case emphasises the importance
of continuing dermatological vigilance in MSH2 families. The same
MSH2 mutations are found in both MTS and Lynch families
(Ponti and Ponz de Leon, 2005), so it is not possible to predict
which families are more likely to develop MTS. The sebaceous
cancers in MTS are possibly less aggressive than sporadic types
(Ponti and Ponz de Leon, 2005), but little is known about survival
in MTS.
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Figure 1 Sebaceous carcinoma: haematoxylin and eosin (100):
multilobulated expansile intradermal tumour showing large polygonal cells
with differentiation into sebaceous cells, altered nuclear/cytoplasmic ratio,
evidence of apoptosis and high mitotic count. Insert: MSH2 immunohis-
tochemical stain (400): Absence of nuclear staining for the MSH2
mismatch repair protein in the tumour cells (the tumour infiltrating
lymphocytes show normal expression of MSH2).
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